Domenico Biasi

Author PubWeight™ 40.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010 2.78
2 Reproductive factors and the risk of scleroderma: an Italian case-control study. Arthritis Rheum 2002 1.67
3 Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. J Clin Periodontol 2008 1.43
4 Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2004 1.29
5 Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005 1.06
6 Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012 1.02
7 The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) 2012 1.02
8 Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011 1.00
9 Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004 0.97
10 Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis. Clin Biochem 2007 0.93
11 Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2004 0.93
12 Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012 0.92
13 Coexistence of systemic sclerosis with other autoimmune diseases. Rheumatol Int 2006 0.89
14 The co-occurrence of Hashimoto thyroiditis in primary Sjogren's syndrome defines a subset of patients with milder clinical phenotype. Rheumatol Int 2012 0.87
15 Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One 2012 0.86
16 Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol 2011 0.86
17 A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 2009 0.86
18 The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 2013 0.86
19 Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost. Rheumatol Int 2011 0.86
20 Proteome analysis of biological fluids from autoimmune-rheumatological disorders. Proteomics Clin Appl 2011 0.85
21 Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006 0.85
22 A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2003 0.84
23 Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin Rheumatol 2008 0.82
24 A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010 0.82
25 Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis. Clin Rheumatol 2013 0.82
26 Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 2009 0.81
27 Pancreatic granulomatous necrotizing vasculitis: a case report and review of the literature. Rheumatol Int 2007 0.81
28 Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009 0.81
29 Psoriasis onset during infliximab treatment: description of two cases. Rheumatol Int 2006 0.80
30 Homocysteine plasma concentration is related to severity of lung impairment in scleroderma. J Rheumatol 2003 0.80
31 Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. PLoS One 2010 0.80
32 Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol 2007 0.80
33 Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 2006 0.80
34 Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum 2011 0.80
35 The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum 2013 0.79
36 Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. Clin Rheumatol 2007 0.79
37 [HLA-DRB1 alleles and rheumatoid arthritis in northern Italy: lack of correlation with disease severity and extra-articular manifestations]. Recenti Prog Med 2005 0.79
38 Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost. Joint Bone Spine 2005 0.78
39 [Homocysteine and rheumatic disease]. Recenti Prog Med 2007 0.78
40 Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis. Clin Rheumatol 2006 0.78
41 Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Dis 2012 0.77
42 Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature. Joint Bone Spine 2002 0.76
43 Dramatic progression of skin involvement in systemic sclerosis after the appearance of anti-Scl70 antibody: a case report. Rheumatol Int 2007 0.75
44 Vitamin D and autoimmune rheumatic diseases. Clin Rheumatol 2011 0.75
45 Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. Rheumatol Int 2006 0.75
46 Systemic sclerosis and malignancy. South Med J 2008 0.75
47 Desensitization to hydroxychloroquine: 4 cases. J Rheumatol 2011 0.75
48 Chlamydophila psittaci subclinical infection in chronic polyarthritis. Clin Exp Rheumatol 2011 0.75
49 Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis. Joint Bone Spine 2009 0.75
50 Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions. Rheumatol Int 2004 0.75
51 Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report. Joint Bone Spine 2010 0.75
52 Clinical images: recurrence of sarcoidosis heralded by Bullous reaction within tribal scarification. Arthritis Rheum 2010 0.75
53 B-flow ultrasound in a case of giant cell arteritis. Clin Rheumatol 2007 0.75
54 Digital amputation in systemic sclerosis: prevalence and clinical associations. A retrospective longitudinal study. J Rheumatol 2012 0.75
55 [Erdheim-Chester disease]. Recenti Prog Med 2004 0.75
56 Unusual bridge ossification of pubic symphysis in diffuse idiopathic skeletal hyperostosis. Rheumatol Int 2011 0.75
57 Iloprost infusion does not reduce oxidative stress in systemic sclerosis. Rheumatol Int 2007 0.75
58 Low levels of activated factor VII in systemic sclerosis. J Thromb Thrombolysis 2006 0.75
59 Clinical images: Neuropathic joint in a patient with calcium pyrophosphate deposition disease. Arthritis Rheum 2003 0.75
60 [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. Recenti Prog Med 2002 0.75
61 Celiac disease in a rheumatology unit: a case study. Rheumatol Int 2007 0.75